Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases

Journal of Autoimmunity

Volumn 39, Issue 1-2, 2012, Pages 112-116

  Shapira, Yinon ^a   Agmon Levin, Nancy ^a   Selmi, Carlo ^b   Petríková, Jana ^c   Barzilai, Ori ^a   Ram, Maya ^a   Bizzaro, Nicola ^d   Valentini, Gabriele ^e   Matucci Cerinic, Marco ^e   Anaya, Juan Manuel ^f   Katz, Bat sheva Porat ^g   Shoenfeld, Yehuda ^a,h  

^a SHEBA MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MILAN   (Italy)

^c L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^d Ospedale Civile   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSIDAD DEL ROSARIO   (Colombia)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^h TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiphospholipid syndrome; Autoimmunity; Geoepidemiology; Parasites; Systemic sclerosis; Toxoplasmosis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CARDIOLIPIN; CENTROMERE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTHROMBIN; SCL 70 ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYOGLOBULINEMIA; ENTERITIS; EUROPE; FEMALE; GEOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SOUTH AND CENTRAL AMERICA; SYSTEMIC SCLEROSIS; THYROID DISEASE; TOXOPLASMA GONDII;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, PROTOZOAN; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BYSTANDER EFFECT; HUMANS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84862501235     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.01.001     Document Type: Article

References (85)

1. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol 2009, 30:409-414.
2. van Riet E., Hartgers F.C., Yazdanbakhsh M. Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology 2007, 212:475-490.
3. Zandman-Goddard G., Shoenfeld Y. Parasitic infection and autoimmunity. Lupus 2009, 18:1144-1148.
4. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010, 34:J168-J177.
5. Shapira Y., Agmon-Levin N., Shoenfeld Y. Geoepidemiology of autoimmune rheumatic diseases. Nat Rev Rheumatol 2010, 6:468-476.
6. Summers R.W., Elliott D.E., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis therapy in Crohn's disease. Gut 2005, 54:87-90.
7. Summers R.W., Elliott D.E., Urban J.F., Thompson R.A., Weinstock J.V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825-832.
8. Girones N., Cuervo H., Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Curr Top Microbiol Immunol 2005, 296:89-123.
9. Abu-Shakra M., Shoenfeld Y. Chronic infections and autoimmunity. Immunol Ser 1991, 55:285-313.
10. Munoz M., Liesenfeld O., Heimesaat M.M. Immunology of Toxoplasma gondii. Immunol Rev 2011, 240:269-285.
11. Dubey J.P., Jones J.L. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol 2008, 38:1257-1278.
12. Halos L., Thebault A., Aubert D., Thomas M., Perret C., Geers R., et al. An innovative survey underlining the significant level of contamination by Toxoplasma gondii of ovine meat consumed in France. Int J Parasitol 2010, 40:193-200.
13. Liesenfeld O. Oral infection of C57BL/6 mice with Toxoplasma gondii: a new model of inflammatory bowel disease?. J Infect Dis 2002, 185(Suppl. 1):S96-101.
14. Blank M., Asherson R.A., Cervera R., Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol 2004, 24:12-23.
15. Chen M., Aosai F., Norose K., Mun H.S., Ishikura H., Hirose S., et al. Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice. Int Immunol 2004, 16:937-946.
16. Adams E.M., Hafez G.R., Carnes M., Wiesner J.K., Graziano F.M. The development of polymyositis in a patient with toxoplasmosis: clinical and pathologic findings and review of literature. Clin Exp Rheumatol 1984, 2:205-208.
17. Tomairek H.A., Saeid M.S., Morsy T.A., Michael S.A. Toxoplasma gondii as a cause of rheumatoid arthritis. J Egypt Soc Parasitol 1982, 12:17-23.
18. Mousa M.A., Soliman H.E., el Shafie M.S., Abdel-Baky M.S., Aly M.M. Toxoplasma seropositivity in patients with rheumatoid arthritis. J Egypt Soc Parasitol 1988, 18:345-351.
19. Balleari E., Cutolo M., Accardo S. Adult-onset Still's disease associated to Toxoplasma gondii infection. Clin Rheumatol 1991, 10:326-327.
20. Tozzoli R., Barzilai O., Ram M., Villalta D., Bizzaro N., Sherer Y., et al. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008, 8:112-115.
21. Wasserman E.E., Nelson K., Rose N.R., Rhode C., Pillion J.P., Seaberg E., et al. Infection and thyroid autoimmunity: a seroepidemiologic study of TPOaAb. Autoimmunity 2009, 42:439-446.
22. Lidar M., Langevitz P., Barzilai O., Ram M., Porat-Katz B.S., Bizzaro N., et al. Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann N Y Acad Sci 2009, 1173:640-648.
23. Zinger H., Sherer Y., Goddard G., Berkun Y., Barzilai O., Agmon-Levin N., et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus 2009, 18:1149-1153.
24. Lidar M., Lipschitz N., Langevitz P., Barzilai O., Ram M., Porat-Katz B.S., et al. Infectious serologies and autoantibodies in Wegener's granulomatosis and other vasculitides: novel associations disclosed using the Rad BioPlex 2200. Ann N Y Acad Sci 2009, 1173:649-657.
25. Sagi L., Baum S., Agmon-Levin N., Sherer Y., Katz B.S., Barzilai O., et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 2011, 10:527-535.
26. Wilcox M.H., Powell R.J., Pugh S.F., Balfour A.H. Toxoplasmosis and systemic lupus erythematosus. Ann Rheum Dis 1990, 49:254-257.
27. Noel I., Balfour A.H., Wilcox M.H. Toxoplasma infection and systemic lupus erythematosus: analysis of the serological response by immunoblotting. J Clin Pathol 1993, 46:628-632.
28. Berkun Y., Zandman-Goddard G., Barzilai O., Boaz M., Sherer Y., Larida B., et al. Infectious antibodies in systemic lupus erythematosus patients. Lupus 2009, 18:1129-1135.
29. Krause I., Anaya J.M., Fraser A., Barzilai O., Ram M., Abad V., et al. Anti-infectious antibodies and autoimmune-associated autoantibodies in patients with type I diabetes mellitus and their close family members. Ann N Y Acad Sci 2009, 1173:633-639.
30. Diagnostic criteria in autoimmune diseases 2008, Humana Press. M.E. Gershwin, R. Cervera, Y. Shoenfeld (Eds.).
31. Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya J.M., Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007, 1108:567-577.
32. Binnicker M.J., Jespersen D.J., Harring J.A. Multiplex detection of IgM and IgG class antibodies to Toxoplasma gondii, rubella virus, and cytomegalovirus using a novel multiplex flow immunoassay. Clin Vaccine Immunol 2010, 17:1734-1738.
33. Potasman I., Araujo F.G., Remington J.S. Toxoplasma antigens recognized by naturally occurring human antibodies. J Clin Microbiol 1986, 24:1050-1054.
34. Vos G.H. Population studies showing cross-reactivity of Toxoplasma gondii antibodies with antibodies to malignant cervical tissue antigens. S Afr Med J 1987, 71:78-82.
35. Yarovinsky F., Sher A. Toll-like receptor recognition of Toxoplasma gondii. Int J Parasitol 2006, 36:255-259.
36. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006, 6:823-835.
37. Shapira Y, Poratkatz BS, Gilburd B, Barzilai O, Ram M, Blank M et al. Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults. Clin Rev Allergy Immunol; in press.
38. Tobon G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010, 35:10-14.
39. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010, 34:J258-J265.
40. Ehrenfeld M. Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 2010, 9:A325-A329.
41. Mackay I.R. Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. Autoimmun Rev 2010, 9:A251-A258.
42. Maverakis E., Miyamura Y., Bowen M.P., Correa G., Ono Y., Goodarzi H. Light, including ultraviolet. J Autoimmun 2010, 34:J247-J257.
43. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 9:A267-A270.
44. Youinou P., Pers J.O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. J Autoimmun 2010, 34:J163-J167.
45. Berkun Y., Padeh S. Environmental factors and the geoepideiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9:A319-A324.
46. Bhat A., Naguwa S., Cheema G., Gershwin M.E. The epidemiology of transverse myelitis. Autoimmun Rev 2010, 9:A395-A399.
47. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 9:A299-A304.
48. Bizzaro N., Tozzoli R., Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum 2007, 56:1736-1744.
49. Borchers A.T., Naguwa S.M., Keen C.L., Gershwin M.E. The implications of autoimmunity and pregnancy. J Autoimmun 2010, 34:J287-J299.
50. Borchers A.T., Naguwa S.M., Shoenfeld Y., Gershwin M.E. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9:A277-A287.
51. Borchers A.T., Uibo R., Gershwin M.E. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010, 9:A355-A365.
52. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun 2010, 34:J207-J219.
53. Chandran V., Raychaudhuri S.P. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010, 34:J314-J321.
54. Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010, 34:J234-J246.
55. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
56. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. J Autoimmun 2010, 34:J276-J286.
57. Chen M., Kallenberg C.G. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev 2010, 9:A293-A298.
58. Deane S., Teuber S.S., Gershwin M.E. The geoepidemiology of immune thrombocytopenic purpura. Autoimmun Rev 2010, 9:A342-A349.
59. Gershwin M.E., Goetzl E.J., Steinberg A.D. Cyclophosphamide: use in practice. Ann Intern Med 1974, 80:531-540.
60. Hemminki K., Li X., Sundquist J., Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J Autoimmun 2010, 34:J307-J313.
61. Hershko A.Y., Naparstek Y. Autoimmunity in the era of genomics and proteomics. Autoimmun Rev 2006, 5:230-233.
62. Hoffmann M.H., Trembleau S., Muller S., Steiner G. Nucleic acid-associated autoantigens: pathogenic involvement and therapeutic potential. J Autoimmun 2010, 34:J178-J206.
63. Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun 2010, 34:J300-J306.
64. Lambert J.F., Nydegger U.E. Geoepidemiology of autoimmune hemolytic anemia. Autoimmun Rev 2010, 9:A350-A354.
65. Leung P.S., Shu S.A., Kenny T.P., Wu P.Y., Tao M.H. Development and validation of gene therapies in autoimmune diseases: epidemiology to animal models. Autoimmun Rev 2010, 9:A400-A405.
66. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
67. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010, 9:A372-A378.
68. Mackay I.R. The etiopathogenesis of autoimmunity. Semin Liver Dis 2005, 25:239-250.
69. Martin P.I., Malizia A.I., Rewald E. A propos time and autoimmunity. Clin Rev Allergy Immunol 2008, 34:380-384.
70. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010, 9:A305-A310.
71. Meyer A., Levy Y. Geoepidemiology of myasthenia gravis. Autoimmun Rev 2010, 9:A383-A386.
72. Meyer N., Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010, 9:A379-A382.
73. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010, 9:A387-A394.
74. Powell J.J., Faria N., Thomas-McKay E., Pele L.C. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010, 34:J226-J233.
75. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:A330-A334.
76. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:A311-A318.
77. Round J.L., O'Connell R.M., Mazmanian S.K. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010, 34:J220-J225.
78. Sands J., Tuscano J.M. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmun Rev 2010, 9:A335-A341.
79. Segelmark M., Hellmark T. Autoimmune kidney diseases. Autoimmun Rev 2010, 9:A366-A371.
80. Selmi C. The worldwide gradient of autoimmune conditions. Autoimmun Rev 2010, 9:A247-A250.
81. Shoenfeld Y., Selmi C., Zimlichman E., Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008, 31:325-330.
82. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010, 9:A271-A276.
83. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010, 34:J322-J326.
84. Tonutti E., Visentini D., Bizzaro N. Interpretative comments on autoantibody tests. Autoimmun Rev 2007, 6:341-346.
85. Zeki A.A., Schivo M., Chan A.L., Hardin K.A., Kenyon N.J., Albertson T.E., et al. Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 2010, 34:J327-J338.